Search results for "Nonalcoholic Fatty Liver Disease"

showing 10 items of 139 documents

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

2019

In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis.We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also c…

AdultLiver CirrhosisMalemedicine.medical_specialtyBiopsydigestive systemGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseBiopsymedicinePrevalenceHumansrisk factorsRisk factorhistory; inflammatory response; progression; risk factorsHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesinflammatory responsemedicine.diseasedigestive system diseasesFatty LiverCross-Sectional StudiesItalyLiver030220 oncology & carcinogenesisLiver biopsyCohort030211 gastroenterology & hepatologyFemalehistoryprogressionSteatohepatitisbusiness
researchProduct

Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the ev…

2013

Biopsy is still the gold standard for the diagnosis of nonalcoholic steatohepatitis but the definition may vary among pathologists, a drawback especially in evaluation of biopsies for clinical trials. We previously developed a scoring system (steatosis, activity, fibrosis [SAF]) allowing the use of an algorithm (fatty liver inhibition of progression [FLIP]) for the classification of liver injury in morbid obesity. The aim of this study was to determine whether the use of the SAF score and FLIP algorithm can decrease interobserver variations among pathologists. In a first session, pathologists categorized 40 liver biopsies of patients with nonalcoholic fatty liver disease (NAFLD) according t…

AdultLiver CirrhosisMalemedicine.medical_specialtyConcordanceBiopsySettore MED/08 - Anatomia PatologicaSeverity of Illness IndexFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineSAF steatosis activity fibrosis.Nonalcoholic fatty liver diseaseBiopsyNAS nonalcoholic steatohepatitis activity scoremedicineHumansAgedObserver VariationHepatologymedicine.diagnostic_testbusiness.industryFatty liverGold standard (test)HepatologyMiddle Agedmedicine.diseaseFatty LiverLiverNASH nonalcoholic steatohepatitiDisease ProgressionFemaleNAFLD nonalcoholic fatty liver diseaseSteatosisbusinessAlgorithmAlgorithmsHepatology (Baltimore, Md.)
researchProduct

Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD

2017

SummaryBackground The accuracy of available non-invasive tools for staging severe fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) is still limited. Aim To assess the diagnostic performance of paired or serial combination of non-invasive tools in NAFLD patients. Methods We analysed data from 741 patients with a histological diagnosis of NAFLD. The GGT/PLT, APRI, AST/ALT, BARD, FIB-4, and NAFLD Fibrosis Score (NFS) scores were calculated according to published algorithms. Liver stiffness measurement (LSM) was performed by FibroScan. Results LSM, NFS and FIB-4 were the best non-invasive tools for staging F3-F4 fibrosis (AUC 0.863, 0.774, and 0.792, respectively), with LSM ha…

AdultLiver CirrhosisMalemedicine.medical_specialtyLiver fibrosisDiagnostic accuracySensitivity and SpecificityGastroenterology03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseLiver stiffnessFibrosisInternal medicineHistological diagnosisNonalcoholic fatty liver diseasemedicineHumansPharmacology (medical)In patientAgedHepatologybusiness.industryNon invasiveGastroenterologyMiddle Agedmedicine.disease030220 oncology & carcinogenesisFemale030211 gastroenterology & hepatologybusinessAlgorithmsAlimentary Pharmacology & Therapeutics
researchProduct

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in pat…

2014

Background & Aims The accuracy of noninvasive tools for the diagnosis of severe fibrosis in patients with nonalcoholic fatty liver disease(NAFLD) in clinical practice is still limited. We aimed at assessing the diagnostic performance of combined noninvasive tools in two independent cohorts of Italian NAFLD patients. Methods We analysed data from 321 Italian patients(179 Sicilian-training cohort, and 142 northern Italy-validation cohort) with an histological diagnosis of NAFLD. Severe fibrosis was defined as fibrosis ≥ F3 according to Kleiner classification. The APRI, AST/ALT, BARD, FIB-4, and NFS scores were calculated according to published algorithms. Liver stiffness measurement(LSM) was …

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyAdolescentLSM ; NAFLD ; NFSBiopsySettore MED/08 - Anatomia PatologicaGastroenterologySeverity of Illness IndexLSM; NAFLD; NFS; Adolescent; Adult; Aged; Alanine Transaminase; Area Under Curve; Aspartate Aminotransferases; Biopsy; Female; Humans; Italy; Liver; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Young Adult; Severity of Illness Index; Hepatology; Medicine (all)Young AdultFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNAFLDNonalcoholic fatty liver diseaseSeverity of illnessBiopsyNFSmedicineHumansLSMAspartate AminotransferasesAgedRetrospective StudiesSettore MED/12 - Gastroenterologiabiologymedicine.diagnostic_testHepatologybusiness.industryMedicine (all)Retrospective cohort studyAlanine TransaminaseHepatologyMiddle Agedmedicine.diseaseAlanine transaminaseItalyLiverArea Under CurveCohortbiology.proteinFemalebusinessLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease W…

2020

HEPAmet Registry.

AdultLiver CirrhosisMalemedicine.medical_specialtySteatosis[SDV]Life Sciences [q-bio]BiopsyLikelihood ratios in diagnostic testingGastroenterologySeverity of Illness IndexDecision Support Techniques03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePositive predicative valueInternal medicineNonalcoholic fatty liver diseaseHOMAMedicineHumansComputingMilieux_MISCELLANEOUSAged2. Zero hungerNASH FIBROSISHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPrognostic FactorGastroenterologyOdds ratioMiddle Agedmedicine.diseasePrognosis3. Good healthCross-Sectional StudiesDiagnostic ToolCirrhosisLiver030220 oncology & carcinogenesisLiver biopsyDiagnostic odds ratio030211 gastroenterology & hepatologyFemalebusinessClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Diagnostic value of MR-based texture analysis for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)

2019

PurposeTo investigate the performance of MR-based texture analysis (TA) for the assessment of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).MethodsFifty-four adult patients (33 females, 21 males, mean age 49.813.5years) with biopsy-proven NAFLD were enrolled and underwent MR imaging on a 1.5T system. TA parameters were extracted on axial noncontrast 3D-GRE T1W images (slice thickness=4.6mm) using a commercially available research software (TexRAD). Receiver operating curves (ROC), areas under the ROC (AUROC) and 95% confidence intervals (CI) were calculated to assess the accuracy of each TA parameter for the diagnosis of significant (F2) and advanced fibrosis (F…

AdultLiver CirrhosisMalemedicine.medical_specialtyUrologyGastroenterology030218 nuclear medicine & medical imaging03 medical and health sciencesImaging Three-Dimensional0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosisInternal medicineImage Interpretation Computer-AssistedNonalcoholic fatty liver diseaseHumansNonalcoholic fatty liver diseaseMedicineRadiology Nuclear Medicine and imagingIn patientTexture analysiAgedRetrospective StudiesRank correlationRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryGastroenterologyMagnetic resonance imagingMiddle AgedHepatologymedicine.diseaseMagnetic Resonance ImagingConfidence intervalLiverMagnetic resonance030220 oncology & carcinogenesisElasticity Imaging TechniquesFemaleSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessHepatic fibrosisHepatic fibrosisSoftwareAbdominal Radiology
researchProduct

The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage

2016

The patatin-like phosholipase domain-containing 3 (PNPLA3) rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate whether additional PNPLA3 coding variants contribute to NAFLD susceptibility, first in individuals with contrasting phenotypes (with early-onset NAFLD vs. very low aminotransferases) and then in a large validation cohort. Rare PNPLA3 variants were not detected by sequencing coding regions and intron-exon boundaries either in 142 patients with early-onset NAFLD nor in 100 healthy individuals with alanine aminotransferase22/20 IU/mL. …

AdultMale0301 basic medicinemedicine.medical_specialtyAdolescentPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseLipid dropletInternal medicineNonalcoholic fatty liver diseasemedicineHumansGenetic Predisposition to DiseaseAlleleChildGeneticsHepatologybiologyMembrane ProteinsAlanine TransaminaseLipaseMiddle AgedHepatologyLipid Metabolismmedicine.diseasedigestive system diseases030104 developmental biologyEndocrinologyHaplotypesLiverAlanine transaminasePatatin-like phospholipaseadolescent; adult; alanine transaminase; case-control studies; child; female; genetic predisposition to disease; haplotypes; humans; lipase; lipid metabolism; liver; male; membrane proteins; middle aged; non-alcoholic fatty liver disease; polymorphism; single nucleotide; hepatologyCase-Control Studiesbiology.proteinFemale030211 gastroenterology & hepatologySteatosisSteatohepatitis
researchProduct

Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.

2017

Background & Aims Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 ± 14; body mass index 27.2 ± 5.3 kg/m2). The primary outco…

AdultMalemedicine.medical_specialtyBiopsyAutoimmune hepatitisHepatic steatosiDiagnostic accuracyGastroenterology03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineNonalcoholic fatty liver diseaseMedicineHumansLiver stiffness measurementAgedFibroScanHepatologymedicine.diagnostic_testbusiness.industryFatty liverReproducibility of ResultsLiver biopsyHepatologyMiddle Agedmedicine.diseaseFatty LiverCross-Sectional StudiesLiverROC Curve030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleSteatosisTransient elastographybusinessNon-alcoholic fatty liver diseaseJournal of hepatology
researchProduct

Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals

2018

Background & Aims: Transient elastography (TE) is a noninvasive technique used to measure liver stiffness to estimate the severity of fibrosis. The range of liver stiffness measurements (LSMs) in healthy individuals is unclear. We performed a systematic review to determine the range of LSMs, examined by TE, in healthy individuals and individuals who are susceptible to fibrosis. Methods: We collected data from 16,082 individuals, in 26 cohorts, identified from systematic searches of Embase, Ovid MEDLINE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for studies of liver stiffness measurements. Studies analyzed included apparently healthy adul…

AdultMalemedicine.medical_specialtyCirrhosisAdolescent03 medical and health sciencesYoung AdultBMI0302 clinical medicineInternal medicineDiabetes mellitusNonalcoholic fatty liver diseasemedicineHumansObesityAgedAged 80 and overCirrhosiAnthropometryHepatologybusiness.industryGastroenterologyBMI; Cirrhosis; Fibroscan; Obesity; Hepatology; GastroenterologyMiddle Agedmedicine.diseaseElasticityHealthy VolunteersFibroscanLiver030220 oncology & carcinogenesisCohortElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleMetabolic syndromeTransient elastographybusinessBody mass indexDyslipidemiaClinical Gastroenterology and Hepatology
researchProduct

The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods

2020

Background. Bariatric surgery patients have a higher prevalence of nonalcoholic fatty liver (NAFL) than the general population; however, its assessment and the accurate staging of fibrosis are often complicated because noninvasive tests are not very accurate in patients with morbid obesity, and liver biopsy cannot be performed as a routine exam. The aim of this study was to evaluate (A) the histological prevalence of NAFL, nonalcoholic steatohepatitis (NASH), and fibrosis in patients undergoing bariatric surgery; (B) the reliability of ultrasound (US) in diagnosing NAFL; and (C) the reliability of various fibrosis scoring systems for defining fibrosis. Methods. US and intraoperative liver b…

AdultMalemedicine.medical_specialtyCirrhosisSettore MED/09 - Medicina InternaArticle SubjectPopulationBariatric SurgeryPrevalence NAFLD Fibrosis Bariatric Surgery Non invasive diagnosis UltrasoundGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseDiabetes mellitusNonalcoholic fatty liver diseasemedicinePrevalenceHumansObesityeducationNonalcoholic steatohepatitis (NASH)Retrospective StudiesUltrasonographyeducation.field_of_studyGeneral Immunology and Microbiologymedicine.diagnostic_testbusiness.industryFatty liverRRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseFibrosisSurgeryObesity Morbidultrasound (US)ROC Curve030220 oncology & carcinogenesisLiver biopsyMedicine030211 gastroenterology & hepatologyFemalebusinessResearch ArticleNonalcoholic fatty liver disease (NAFLD)BioMed Research International
researchProduct